Physician profile
Timothy D Hooper
NPI 1629097399
$5,551.46
in general payments reported to CMS, 2019-2025
39 companies · $617 in 2025
The $617 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $1,075 · 2021: $825 · 2022: $862 · 2023: $651 · 2024: $659 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859 · Education: $68.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.10 |
| Education | $68.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $693.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $536.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $526.80 | 2019-2023 | Xarelto |
| Pfizer INC. | $417.06 | 2019-2024 | |
| Allergan, INC. | $404.08 | 2019-2021 | |
| Abbvie INC. | $381.33 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $342.07 | 2019-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $283.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.22 | 2019-2023 | Stiolto Respimat |
| Biohaven Pharmaceutical Holding Company LTD. | $155.26 | 2022 | |
| Indivior INC. | $147.09 | 2019-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $143.19 | 2019-2021 | |
| Lilly USA, LLC | $142.40 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $118.40 | 2019-2022 | |
| Corcept Therapeutics | $89.35 | 2024-2025 | Korlym |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.